This site is intended only for healthcare professionals resident in the United Kingdom

The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.


Consider Bosulif when switching TKI1​​​​​​​

*Low cardiac events occurrence defined as 5.2% for bosutinib cf 5.3% for imatinib in clinical trials.2

BFORE Study:

First-line data

Study 200:

Second-line data

Recommended starting dose in first-line1

400mg BOSULIF for adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)

Recommended starting dose in second-line and beyond1

500mg BOSULIF for adult patients with CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options

Dose Adjustment1

100mg BOSULIF for dose escalation and reduction in increments between 300mg and 600mg (known as range of efficacy), depending on patient response and tolerability. Please refer to Summary of Product Characteristics for full guidance on when to escalate or reduce BOSULIF dosing by 100mg increments.

For information on dosing and dose adjustments, view Dosing Guide

Download here

Colour and size of tablets shown are not representative of the actual tablets and are for illustrative purposes only. 100 mg tablets width: 5.6 mm, length: 10.7 mm; 400 mg tablets width: 8.8 mm, length: 16.9 mm; 500 mg tablets width: 9.5 mm, length: 18.3 mm.1 

Consider Bosulif  when you make a TKI switch

AP, accelerated phase; BP, blast phase; CML, chronic myelogenous leukaemia; CP, chronic phase; Ph+ CML; Philadelphia chromosome-positive chronic myelogenous leukaemia, TKI; tyrosine kinase inhibitor.

Explore more


Watch Prof. Richard Clark discuss the holistic approach to treatment decisions for patient with CML

Learn more

New challenges: long-term TKI therapy

Hear Dr. Alex Lyon’s views on long-term TKI treatment in an ageing patient population video

Learn more

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
  1.  BOSULIF Summary of Product Characteristics for Great Britain click here. BOSULIF Summary of Product Characteristics for Northern Ireland click here.
  2. Cortes JE, et al. J Clin Oncol 2018;36:231–237.
  3. Gambacorti-Passerini C, et al. Am J Hematol 2014;89:732–742.
  4. Cortes JE, et al. Presented at American Society of Clinical Oncology Annual Meeting, 2018; Oral presentation 7002.
  5. Gambacorti-Passerini C, et al. Haematologica 2018;103:1298–1307.
  6. Valent P, et al. Blood 2015;125:901–906
PP-BOS-GBR-1301. September 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020